上海微创电生理医疗科技股份有限公司 独立董事候选人声明与承诺 本人 丁建东 ，已充分了解并同意由提名人上海微创电生理医疗科技股份 有限公司董事会提名为上海微创电生理医疗科技股份有限公司第四届董事会独 立董事候选人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影 响本人担任上海微创电生理医疗科技股份有限公司独立董事独立性的关系，具体 声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； 1 （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进 ...

上海微创电生理医疗科技股份有限公司 独立董事候选人声明与承诺 本人 张东 ，已充分了解并同意由提名人上海微创电生理医疗科技股份有 限公司董事会提名为上海微创电生理医疗科技股份有限公司第四届董事会独立 董事候选人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影响 本人担任上海微创电生理医疗科技股份有限公司独立董事独立性的关系，具体声 明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （七）中国人民银行《股份制商业银行独立董事和外部监事制度指引》等的 相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业人 1 员监督管理办法》等的相关 ...

证券代码：688351 证券简称：微电生理 公告编号：2025-030 上海微创电生理医疗科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 22 日 14 点 30 分 召开地点：上海市浦东新区周浦镇天雄路 588 弄 23 号楼 3 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 22 日 至2025 年 12 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 ...

上海微创电生理医疗科技股份有限公司董事会提名委员会 1、经审阅张东先生、李亦争先生、丁建东先生的个人履历等相关资料，其 与公司第一大股东、持股 5%以上股东及其他董事、高级管理人员之间不存在关 联关系，不存在《公司法》等法律法规及《公司章程》规定的不得担任上市公司 独立董事的情形，符合中国证监会《上市公司独立董事管理办法》及公司《独立 董事工作制度》对于上市公司独立董事的任职资格与独立性要求。 2、张东先生、李亦争先生、丁建东先生具有丰富的专业知识，熟悉相关法 律、行政法规、部门规章及其他规范性文件，其教育背景、工作经历及专业经验 均能够胜任独立董事的职责要求。 综上，我们同意提名张东先生、李亦争先生、丁建东先生为公司第四届董事 会独立董事候选人，并同意将该事项提交公司第三届董事会第十八次会议审议。 上海微创电生理医疗科技股份有限公司 关于公司独立董事候选人任职资格的审查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董 事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件以及《上海 微创电生理医 ...

证券研究报告 医药生物 | 医疗器械 非金融|公司点评报告 hyzqdatemark 2025 年 12 月 01 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 林海霖 SAC：S1350524050002 linhailin@huayuanstock.com 市场表现： 请务必仔细阅读正文之后的评级说明和重要声明 事件：公司发布公告，一次性使用压力导管(PFA 导管)获得国内药品监督管理局注册 申请，产品矩阵持续丰富。 联系人 海外营收稳步增长，扣非归母净利润扭亏。2025 年前三季度，公司实现营业收入 3.36 亿元（yoy+15.65%），归母净利润 0.42 亿元（yoy+0.46%），扣非归母净利润 0.24 亿元。第三季度，营业收入 1.13 亿元（yoy+21.78%），归母净利润 0.09 亿元 （yoy-62.56%），扣非归母净利润 0.03 亿元，同比扭亏为盈。前三季度海外市场中 拉美、欧洲、中东及非洲，收入均保持较高增长态势，冷冻全套产品于 25Q2 获得 CE 认证，已在部分海外市场启动推广。 创新医疗器械获批，电生 ...

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

Summary of Medical Device and Healthcare Services Industry Conference Call Industry Overview - The medical device and healthcare services industry is expected to continue its recovery, with long-term investment opportunities emerging for 2026. [1][2] - The impact of centralized procurement is gradually diminishing, with some demand expected to be delayed until 2025. [1][2] Key Insights and Arguments - **Growth Drivers**: The industry is projected to experience steady growth in 2026 due to inventory clearance, new product launches, and growth in overseas markets. [1][2] - **Cautious Outlook from Leading Companies**: Some leading companies have provided cautious performance guidance for the upcoming periods. [1][2] - **Focus Areas**: Specific segments such as orthopedics (e.g., Spring Medical) and e-commerce connections (e.g., New Pulse Medical) are highlighted as areas of interest. [1][3] - **RVD Sector**: The RVD sector is expected to perform well in 2026, driven by a high proportion of overseas revenue (40%). [1][3] - **Electrophysiology**: Companies like Huatai are noted for their cost-effective valuations, with expectations of significant growth driven by new products. [1][5] - **IVD Sector**: The IVD sector is anticipated to face challenges in 2025 but is expected to gradually recover starting in Q4. [1][10] Company-Specific Developments - **Huatai**: Despite recent stock price adjustments, Huatai is expected to see a profit growth rate of over 25% in 2026, supported by the launch of its innovative product TFA. [5] - **Aohua Endoscopy**: The company is expected to see revenue growth due to improved bidding data and the introduction of competitive new products. [6] - **Mindray**: Aiming to penetrate over 2,000 key hospitals in the IVD sector, with potential market share growth due to acquisitions. [11] - **New Industry**: Expected to maintain over 20% growth in overseas markets despite domestic pricing pressures. [11] Investment Opportunities - **Current Market Position**: Many medical device companies, including Mindray and Huatai, are viewed as having long-term value and low valuation opportunities. [7][8] - **Potential High-Growth Companies**: Companies like Microelectrophysiology and Ruimaite are highlighted as having potential for exceeding expectations in business growth. [8] - **2026 Performance Expectations**: The medical device sector is expected to accelerate in 2026, with companies like Mindray and Kaidiya projected to improve performance due to better bidding trends and reduced inventory pressure. [9] Challenges and Risks - **IVD Sector Challenges**: The IVD sector is facing price pressures and a decline in volume in 2025, but is expected to stabilize in 2026. [10] - **High-Value Consumables**: The sector is experiencing challenges due to centralized procurement policies, but opportunities for valuation recovery exist in segments where risks have not fully cleared. [13][14] Future Outlook - **Serious Medical vs. Consumer Medical**: Serious medical is under pressure but expected to recover in the long term, particularly in oncology. Consumer medical is seen as having significant growth potential due to low penetration rates. [19] - **International Expansion**: Domestic companies are increasingly focusing on international markets, with various strategies being employed to enhance their global presence. [17][18] This summary encapsulates the key points discussed in the conference call regarding the medical device and healthcare services industry, highlighting growth prospects, company-specific developments, investment opportunities, and potential challenges.

关于一次性使用压力监测心脏脉冲电场消融导管 获批上市的自愿披露公告 证券代码：688351 证券简称：微电生理 公告编号：2025-028 上述注册申请的取得仅代表一次性使用压力监测心脏脉冲电场消融导管获得国内市场准入资格，产品上 市后的实际销售情况受到多重因素影响，目前尚无法预测其对公司未来业务的具体影响。敬请广大投资 者谨慎投资，注意投资风险。 上海微创电生理医疗科技股份有限公司 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，上海微创电生理医疗科技股份有限公司（以下简称"公司"）一次性使用压力监测心脏脉冲电场消 融导管获得国家药品监督管理局注册申请（国械注准20253012351）。该产品基于应变片原理的压力传 感器设计，结合脉冲电场技术、磁场定位技术、盐水灌注技术，与心脏脉冲电场消融设备配合使用，可 用于心律失常治疗；与三维心脏电生理标测系统配合使用，可提供导管在心内的位置信息以及进行导管 头端和心壁之间触点压力的实时测量。上述医疗器械注册证的取得，实现了公司"射频+冷冻+脉冲"三 大消融能量产品 ...

证券日报网讯 11月21日晚间，微电生理发布公告称，近日，上海微创电生理医疗科技股份有限公司 （以下简称"公司"）一次性使用压力监测心脏脉冲电场消融导管获得国家药品监督管理局注册申请（国 械注准20253012351）。 （文章来源：证券日报） ...

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]